Testing treatments for marginal zone lymphoma that returned
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares three treatment combinations for marginal zone lymphoma (a slow-growing blood cancer) that has come back or not improved after earlier treatment. It tests a new drug alone or with another drug to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have marginal zone lymphoma that came back or didn't improve after at least one prior treatment that targeted CD20 (a protein on the cancer cells).
- You must have at least one measurable sign of disease, like a lymph node larger than 1.5 cm or an enlarged spleen.
- You must have symptoms from the lymphoma, such as fever, weight loss, night sweats, or other signs that more treatment is needed.
- You must be 18 or older and able to care for yourself (performance status 0-2).
- Your blood counts and organ function must be within acceptable ranges, such as adequate white blood cells, platelets, and kidney and liver function.
- You cannot have had certain treatments recently, like CAR-T therapy, stem cell transplants, or certain vaccines, within specific timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
This trial tests a new combination of two drugs for people with a type of lymphoma called marginal zone lymphoma who have not had prior systemic treatment. It aims to see if the combination can shrink or control the cancer and improve quality of life.
This trial tests a personalized treatment plan for people with newly diagnosed marginal zone lymphoma (MZL). The treatment is based on a risk score and aims to be more targeted than standard chemotherapy.
This trial tests a combination of two drugs—nemtabrutinib (a BTK inhibitor that targets cancer cells) and rituximab (an antibody drug)—to treat marginal zone lymphoma, a type of blood cancer. The study aims to see if this combination works better than standard treatments.
Hear when a new Recurrent Nodal Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.